Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tiaozhong Formula (TZF) is a Traditional Chinese Medicine (TCM) herbal decoction developed by the Eye Hospital of the China Academy of Chinese Medical Sciences. It is specifically indicated for the treatment of diabetic macular edema (DME), a common complication of diabetic retinopathy characterized by fluid accumulation in the macula. The formula is based on the TCM principle of "regulating the middle" (Tiaozhong), which focuses on strengthening the spleen and resolving dampness to address the underlying pathology of fluid retention. Clinical research suggests that Tiaozhong Formula exerts its therapeutic effects by modulating inflammatory cytokines and inhibiting vascular endothelial growth factor (VEGF) expression, thereby reducing macular thickness and improving visual acuity. It is typically administered as an oral decoction and has been studied both as a monotherapy and as an adjunctive treatment to standard intravitreal anti-VEGF injections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tiaozhong Formula.